New vaccine duo takes on deadly skin cancer
NCT ID NCT05912244
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two experimental vaccines (IO102/IO103) to the standard drug combination of nivolumab and relatlimab can shrink or control advanced melanoma that cannot be removed by surgery. About 43 adults with untreated stage III or IV melanoma will receive the combination. The main goal is to see how many patients have their tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hartford Healthcare Alliance (Data Collection Only)
Hartford, Connecticut, 06102, United States
-
Lehigh Valley Health Network (Data Collection Only)
Allentown, Pennsylvania, 18103, United States
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a lighter immunotherapy schedule keep advanced cancers in check?